Using the Fisher Exact test and p = .05, 21 patient mortality with leronlimab and 24 patient mortality in SOC gives a power of 87.2%.

Which would be more than sufficient for a BLA submission and the FDA standard of "must prove efficacy". But the standard for an EUA is "may prove beneficial" which is a much lower standard.